BlackRock
EIKN

BlackRock’s Eikon Therapeutics EIKN Stock Holding History

BlackRock’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.9M Buy
4,281,425
+962,046
+29% +$9.82M ﹤0.01% 2615
2026
Q1 		$35.1M Buy
+3,319,379
New +$44.4M ﹤0.01% 2740

Other funds holding EIKN

MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

BlackRock's EIKN Position: Q2 2026 in Review

BlackRock increased its Eikon Therapeutics (EIKN) stake by 29% in Q2 2026, buying an estimated $9.82M and bringing the position to 4,281,425 shares worth $55.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2615.

BlackRock first reported a position in EIKN in Q1 2026 and has held it in 2 quarters since. 70 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

  • BlackRock held 4,281,425 shares of Eikon Therapeutics worth $55.9M as of Q2 2026.
  • BlackRock bought 962,046 Eikon Therapeutics shares in Q2 2026, an estimated $9.82M.
  • Eikon Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2615 holding.
  • BlackRock first reported a position in Eikon Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 70 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.